Fred Callori
Managing Director of Venture @ Perceptive Advisors
Boston, United States
Fred Callori is a Series A investor at Perceptive Advisors in Boston focused on Medical and Biotechnology. Fred Callori is based out of New York, New York, and is the Managing Director of Venture of Perceptive Advisors and also serves as the Board of Directors of LeonaBio. Fred previously worked at Xontogeny as a Senior Partner. Fred Callori attended Boston University School of Law.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Fred Callori invests in
Stages Fred Callori invests in
Countries Fred Callori invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 4 (50%)
- Biotechnology 4 (50%)
- Biopharma 3 (38%)
- Health Care 2 (25%)
- Hardware 1 (13%)
Stage
- Series A 4 (50%)
- Seed 2 (25%)
- Series B 2 (25%)
Country
- United States 6 (75%)
- Switzerland 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Neurosterix aims to create novel medicines based on allosteric modulation that overcome the limitations of traditional treatments and have the potential to significantly enhance patients' lives. | $65M / Series A / Apr 03, 2024 | ||
| Tellus Therapeutics is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury. It was founded in 2018 and is based in Hillsborough, North Carolina. | $35M / Series A / Dec 13, 2022 | ||
| Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company, focuses on the development and commercialization of late-stage women’s health products. It offers lasofoxifene, a selective estrogen receptor modulator for the treatment of vulvovaginal atrophy, as well as treatment and prevention of post-menopausal osteoporosis. The company wasfounded in 2014 and is headquartered in Columbus, Ohio. | $40M / Series A / Nov 15, 2021 | ||
| Juno Diagnostics is a health technology company democratizing access to high-value genetic information. The company is developing simple, cost-effective devices that enable point-of-need genetic testing. It was founded in 2017 and is based in San Diego, California. | $25M / Series A / May 12, 2021 | ||
| Peroxitech Therapeutics operates as a biopharmaceutical company developing PIP-2 to reverse acute lung injury (ALI) by targeting the cytokine storm cascade process. | Seed / May 12, 2021 | ||
| Tellus Therapeutics is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury. It was founded in 2018 and is based in Hillsborough, North Carolina. | $2M / Seed / May 12, 2021 | ||
| Forge Biologics is a gene therapy development engine, focused on enabling access to life-changing gene therapies and helping bring them from an idea into reality. The company partners with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups.It was founded in 2020 and headquartered inGrove City, Ohio. | $120M / Series B / Apr 29, 2021 | ||
| Forge Medical, Inc. provides hemostasis devices for dialysis units and phlebotomy laboratories in the United States. It offers VasoStat, a device for assisting hemostasis in patients with various problems, including prolonged bleeding following dialysis graft, fistula puncture, and routine blood draws. The company was incorporated in 2009 and isbased in Lancaster, Pennsylvania. | $120M / Series B / Apr 29, 2021 |
Co-Investors
About Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while investing. The firm typically invests in the biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York,New York.
Perceptive Advisors Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ellen Hukkelhoven
Head of Investment Research
|
|||
|
Fred Callori
Managing Director of Venture
|
|||
Joseph Edelman
CEO & Founder
|
|||
Orly Mishan
Managing Director, Perceptive Discovery
|
|||
Adam Stone
Chief Investment Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Fred Callori invest in?
Fred Callori invests primarily in Medical, Biotechnology and Biopharma startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Fred Callori?
Public channels for Fred Callori include LinkedIn and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Fred Callori last invest?
The most recent investment recorded for Fred Callori closed in Apr 2024. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
